Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 15/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | FECH | P22830 | 1/20 | 0.37 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629023 | 0.92 | IGF1R (0.43) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL8399507 | 0.92 | IGF1R (0.43) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL12648325 | 0.88 | PDPK1 (0.39) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL12648432 | 0.86 | MTOR (0.50) | TNK2CSNK2A2RIPK2RETNQO2 | |
| SCHEMBL10240939 | 0.83 | TNK2 (0.40) | TNK2CSNK2A2RIPK2RETNQO2 | |
| SCHEMBL13629020 | 0.78 | TNK2 (0.47) | TNK2PDPK1ABL1EGFRRAF1 | |
| SCHEMBL13629449 | 0.77 | MTOR (0.43) | TNK2IGF1RCSNK2A2RIPK2RET | |
| SCHEMBL12648416 | 0.77 | TNK2 (0.53) | TNK2CSNK2A2RIPK2RETNQO2 | |
| SCHEMBL8399556 | 0.77 | MTOR (0.51) | TNK2CSNK2A2RIPK2RETNQO2 | |
| SCHEMBL6941875 | 0.76 | MTOR (0.60) | TNK2PDPK1ABL1EGFRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | TNK2 144/4885PDPK1 9/4885ABL1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.